Subject: Fwd: 1101S94592 - PI Masten - IRB - APVD Continuing Review
Date: Wednesday, February 26, 2014 at 7:28:49 AM Central Standard Time
From: Ann Masten
To: Jerry Slotkin
CC: Amanda Wenzel, Jake Anderson, Stephanie Carlson, Philip Zelazo

Here is the annual renewal. Approval for change in protocol follows.

Ann S. Masten, PhD
Irving B. Harris Professor of Child Development
Distinguished McKnight University Professor
Institute of Child Development
University of Minnesota, Twin Cities
51 East River Road
Minneapolis MN 55455
USA

Ofc 612-624-0215

Fax 612-624-6373

---------- Forwarded message ----------
From: <irb@umn.edu>
Date: Thu, Nov 21, 2013 at 11:16 PM
Subject: 1101S94592 - PI Masten - IRB - APVD Continuing Review
To: amasten@umn.edu

TO : amasten@umn.edu, zelazo@umn.edu, smc@umn.edu, buckn019@umn.edu, ande2523@umn.edu, wenz0107@umn.edu, casey312@umn.edu, hels0036@umn.edu, zjacobso@umn.edu,

The IRB: Human Subjects Committee renewed its approval of the referenced study listed below:

Study Number: 1101S94592

Principal Investigator: Ann Masten

Expiration Date: 11/19/2014

Approval Date: 11/20/2013

Title(s):
Assessment of Executive Function for the National Children's Study

This e-mail confirmation is your official University of Minnesota HRPP notification of continuing review approval. You will not receive a hard copy or letter. This secure electronic notification between password protected authentications has been deemed by the University of Minnesota to constitute a legal signature.

You may go to the View Completed section of http://eresearch.umn.edu/ to view or print your continuing review submission.

For grant certification purposes you will need this date and the Assurance of Compliance number, which is FWA00000312 (Fairview Health Systems Research FWA00000325, Gillette Childrens Specialty Healthcare FWA00004003). Approval will expire one year from that date. You will receive a report form two months before the expiration date.

In the event that you submitted a consent document with the continuing review form, it has also been reviewed and approved. If you provided a summary of subjects' experience to include non-UPIRTSO events, these are hereby acknowledged.

As Principal Investigator of this project, you are required by federal regulations to inform the IRB of any proposed changes in your research that will affect human subjects. Changes should not be initiated until written IRB approval is received. Unanticipated problems and adverse events should be reported to the IRB as they occur. Results of inspections by any external regulatory agency (i.e. FDA) must be reported immediately to the IRB. Research projects are subject to continuing review.

If you have any questions, please call the IRB office at (612) 626-5654.

The IRB wishes you continuing success with your research.